BIOMAT Database Logo BIOMAT Database Logo

[Heparin therapy in chronic cor pulmonale]. 1987

G Scripcaru, and G Ungureanu, and V Ambăruş, and S Ionescu, and D Iordăcheanu, and G Popa

UI MeSH Term Description Entries
D011660 Pulmonary Heart Disease Hypertrophy and dilation of the RIGHT VENTRICLE of the heart that is caused by PULMONARY HYPERTENSION. This condition is often associated with pulmonary parenchymal or vascular diseases, such as CHRONIC OBSTRUCTIVE PULMONARY DISEASE and PULMONARY EMBOLISM. Cor Pulmonale,Disease, Pulmonary Heart,Diseases, Pulmonary Heart,Heart Disease, Pulmonary,Heart Diseases, Pulmonary,Pulmonary Heart Diseases
D002908 Chronic Disease Diseases which have one or more of the following characteristics: they are permanent, leave residual disability, are caused by nonreversible pathological alteration, require special training of the patient for rehabilitation, or may be expected to require a long period of supervision, observation, or care (Dictionary of Health Services Management, 2d ed). For epidemiological studies chronic disease often includes HEART DISEASES; STROKE; CANCER; and diabetes (DIABETES MELLITUS, TYPE 2). Chronic Condition,Chronic Illness,Chronically Ill,Chronic Conditions,Chronic Diseases,Chronic Illnesses,Condition, Chronic,Disease, Chronic,Illness, Chronic
D003131 Combined Modality Therapy The treatment of a disease or condition by several different means simultaneously or sequentially. Chemoimmunotherapy, RADIOIMMUNOTHERAPY, chemoradiotherapy, cryochemotherapy, and SALVAGE THERAPY are seen most frequently, but their combinations with each other and surgery are also used. Multimodal Treatment,Therapy, Combined Modality,Combined Modality Therapies,Modality Therapies, Combined,Modality Therapy, Combined,Multimodal Treatments,Therapies, Combined Modality,Treatment, Multimodal,Treatments, Multimodal
D004211 Disseminated Intravascular Coagulation A disorder characterized by procoagulant substances entering the general circulation causing a systemic thrombotic process. The activation of the clotting mechanism may arise from any of a number of disorders. A majority of the patients manifest skin lesions, sometimes leading to PURPURA FULMINANS. Consumption Coagulopathy,Coagulation, Disseminated Intravascular,Disseminated Coagulation, Intravascular,Intravascular Coagulation, Disseminated,Intravascular Disseminated Coagulation,Coagulation, Intravascular Disseminated,Coagulations, Disseminated Intravascular,Coagulations, Intravascular Disseminated,Coagulopathies, Consumption,Coagulopathy, Consumption,Consumption Coagulopathies,Disseminated Coagulations, Intravascular,Disseminated Intravascular Coagulations,Intravascular Coagulations, Disseminated,Intravascular Disseminated Coagulations
D004341 Drug Evaluation Any process by which toxicity, metabolism, absorption, elimination, preferred route of administration, safe dosage range, etc., for a drug or group of drugs is determined through clinical assessment in humans or veterinary animals. Evaluation Studies, Drug,Drug Evaluation Studies,Drug Evaluation Study,Drug Evaluations,Evaluation Study, Drug,Evaluation, Drug,Evaluations, Drug,Studies, Drug Evaluation,Study, Drug Evaluation
D006493 Heparin A highly acidic mucopolysaccharide formed of equal parts of sulfated D-glucosamine and D-glucuronic acid with sulfaminic bridges. The molecular weight ranges from six to twenty thousand. Heparin occurs in and is obtained from liver, lung, mast cells, etc., of vertebrates. Its function is unknown, but it is used to prevent blood clotting in vivo and vitro, in the form of many different salts. Heparinic Acid,alpha-Heparin,Heparin Sodium,Liquaemin,Sodium Heparin,Unfractionated Heparin,Heparin, Sodium,Heparin, Unfractionated,alpha Heparin
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D013997 Time Factors Elements of limited time intervals, contributing to particular results or situations. Time Series,Factor, Time,Time Factor

Related Publications

G Scripcaru, and G Ungureanu, and V Ambăruş, and S Ionescu, and D Iordăcheanu, and G Popa
[Therapy of chronic cor pulmonale].
November 1993, Zeitschrift fur die gesamte innere Medizin und ihre Grenzgebiete,
G Scripcaru, and G Ungureanu, and V Ambăruş, and S Ionescu, and D Iordăcheanu, and G Popa
[Therapy of chronic cor pulmonale].
September 1970, Die Medizinische Welt,
G Scripcaru, and G Ungureanu, and V Ambăruş, and S Ionescu, and D Iordăcheanu, and G Popa
[Oxygen therapy in chronic cor pulmonale].
January 1975, Verhandlungen der Deutschen Gesellschaft fur Innere Medizin,
G Scripcaru, and G Ungureanu, and V Ambăruş, and S Ionescu, and D Iordăcheanu, and G Popa
Pulmonary therapy in chronic cor pulmonale.
January 1957, Transactions. American College of Cardiology,
G Scripcaru, and G Ungureanu, and V Ambăruş, and S Ionescu, and D Iordăcheanu, and G Popa
[Chronic cor pulmonale; cor pulmonale without anoxemia].
June 1951, Medicina,
G Scripcaru, and G Ungureanu, and V Ambăruş, and S Ionescu, and D Iordăcheanu, and G Popa
[Pipolphen therapy of chronic cor pulmonale].
December 1961, Tuberkulozis,
G Scripcaru, and G Ungureanu, and V Ambăruş, and S Ionescu, and D Iordăcheanu, and G Popa
[Prolonged therapy of chronic cor pulmonale].
February 1970, Minerva medica,
G Scripcaru, and G Ungureanu, and V Ambăruş, and S Ionescu, and D Iordăcheanu, and G Popa
[Effortil therapy of chronic cor pulmonale].
June 1959, Medizinische Klinik,
G Scripcaru, and G Ungureanu, and V Ambăruş, and S Ionescu, and D Iordăcheanu, and G Popa
[The therapy of chronic cor pulmonale].
August 1958, Archivio "E. Maragliano" di patologia e clinica,
G Scripcaru, and G Ungureanu, and V Ambăruş, and S Ionescu, and D Iordăcheanu, and G Popa
[Vasodilator therapy of chronic cor pulmonale].
September 1986, Nihon Kyobu Shikkan Gakkai zasshi,
Copied contents to your clipboard!